China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

Novo's Victoza (liraglutide) daily GLP-1 is already well established and the company hopes to build on its success with semaglutide and its more convenient weekly dosing schedule. Novo is also ...

Blockbuster GLP-1 medications are changing patient care, impacting surgery volumes and reshaping the financial landscape of the healthcare industry.

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

A new study presented at the American Academy of Orthopedic Surgeons meeting reveals the need to stop taking GLP-1 agonists ...

Bacterial vaginosis affects nearly a third of women worldwide and can cause infertility, premature births and newborn deaths.

Intensive management of diabetes pays fewer dividends as patients age and raises the chances of hypoglycemia. But many people ...

Advt Eli Lilly's Trulicity (dulaglutide) was the most commonly used GLP-1 drug in the study. Some patients received Novo Nordisk's Ozempic (semaglutide) or the company's older Victoza (liraglutide).

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...